Clinical trials: RSV, open to volunteers
Respiratory Viral Infection
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected…
- Trial name
- RESPIRE (NCT07633288)
- Testing
- AP1189, 100 mg
- Where
- 11 sites in Bosnia and Herzegovina, Montenegro and 2 more
- Volunteers
- 96 people
- Sponsor
- SynAct Pharma Aps
Respiratory Syncytial Virus (RSV)
Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
This trial employs a randomized, double-blind, placebo/positive control, and dose-finding design to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SIBP-A16…
- Trial name
- NCT07363837
- Testing
- SIBP-A16 injection, Nirsevimab, SIBP-A16 buffer solution
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Respiratory Syncytial Virus Infections
Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV
A short description, 5000 characters Intro: Respiratory Syncytial Virus (RSV) is a frequent, ubiquitous agent of respiratory viral infections.
- Trial name
- ARF-RSV (NCT06197152)
- Testing
- Nasopharyngeal swabs and biological collection
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Infections
Study of Viral Respiratory Infections
Acute viral respiratory infections are a major public health problem, as they cause mortality especially in pediatric patients, over 65 and those with co-morbidities.
- Trial name
- NCT06764381
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Respiratory Syncytial Virus Infections
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the…
- Trial name
- NCT07582796
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant)
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Respiratory Infections, Antibiotic
Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).
- Trial name
- TROD-VILLE (NCT07243249)
- Testing
- TROD
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bronchiolitis; Respiratory Syncytial Virus
COVID-19 Impact on RSV Emergency Presentations
Bronchiolitis is a very common winter disease that normally affects children less than one year of age. It is a common reason for parents and carers to bring their child to an Emergency Department (ED) and the frequent need for…
- Trial name
- BronchSTART (NCT04959734)
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospitals, Leicester
Respiratory Syncytial Virus Infections
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia…
- Trial name
- NCT07658534
- Testing
- Ziresovir (AK0529)
- Where
- 9 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the…
- Conditions
- RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy, Healthy
- Trial name
- CosTaR (NCT07097012)
- Testing
- Tdap Vaccine Administration, RSV Vaccine
- Where
- 4 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Immunization Research Network
RSV, mRNA Vaccine
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
To evaluate the safety of Sinovac RSV mRNA among participants aged ≥18 years
- Trial name
- NCT07418229
- Testing
- Low-dose RSV mRNA vaccine, High-dose RSV mRNA vaccine
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Respiratory Syncytial Virus (RSV)
A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution
A phase II clinical study to evaluate the efficacy and safety of YKYY018 for inhalation solution in adult participants with respiratory syncytial virus infection
- Trial name
- NCT07808268
- Testing
- YKYY018 for Inhalation Solution
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Respiratory Syncytial Virus (RSV)
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
- Trial name
- NCT07839871
- Testing
- RSVpreF
- Where
- 2 sites in United States, Japan
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Mucosal Cytokine Profile of Patients (Type I and III Interferons, Pro-inflammatory Cytokines)
ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial Environment
Among children aged ≤ 6 months included in the ENVIE study, the ENVIE_ancillaire study will be offered to cases of RSV infection or to controls.
- Trial name
- ENVIEANCILLAIR (NCT07698769)
- Testing
- a study of the mucosal immune signature associated with hospitalised RSV bronchiolitis
- Where
- 3 sites in France
- Volunteers
- 110 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
RSV Immunization, HIV
Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young infants in Canada. While most babies recover, RSV can cause severe breathing problems and place major stress on families and the health system.
- Trial name
- SHIELD-RSV (NCT07693166)
- Testing
- RSVpreF
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Bronchiolitis, Clinical Phenotype
Short-Term Enteral Nutrition for Infants With Bronchiolitis in Pediatric Emergency Departments
Bronchiolitis is a common viral infection of the small airways that affects infants, particularly during respiratory syncytial virus epidemics.
- Conditions
- Bronchiolitis, Clinical Phenotype, Nutritionnal Impairment, Short-Term Enteral Nutrition
- Trial name
- STENP-PER (NCT07901400)
- Testing
- Usual inpatient bronchiolitis care, STENP-PER care pathway
- Where
- 8 sites in France
- Volunteers
- 448 people
- Sponsor
- Hospices Civils de Lyon
Influenza Viruses, Respiratory Syncytial Virus (RSV)
ELderly REspiratory VIral Cohort
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and…
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV)
- Trial name
- ELREVI (NCT07813481)
- Testing
- Respiratory viral infection
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical practice settings.
- Trial name
- NCT07200206
- Testing
- Nirsevimab
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sanofi